IDN 1965

Drug Profile

IDN 1965

Latest Information Update: 27 Nov 2007

Price : $50

At a glance

  • Originator Idun Pharmaceuticals
  • Class Hepatoprotectants; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Caspase inhibitors; Caspase-3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Reperfusion injury

Most Recent Events

  • 19 Apr 2005 Idun Pharmaceuticals has been acquired by Pfizer
  • 20 Feb 2002 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 12 Nov 2000 Preclinical development for Heart failure in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top